PRACTICAL ONCOLOGY JOURNAL ›› 2010, Vol. 24 ›› Issue (1): 20-23.doi: 10.3969/j.issn.1002-3070.2010.01.005

Previous Articles     Next Articles

Screening on the serum protein markers for predicting lung adenocarcinoma chemotherapy sensitivity with the SELDI-TOF-MS technique

ZHAO Jian1, XU Wei1, WANG Yuandong1, GUO Ailin2, XUE Xingyang1, LI Hongsheng1, HAN Guodong1, FU Wenfan1   

  1. 1.Department of Pulmonary Tumour surgery,Affiliated Tumour Hospital of Guangzhou Medical University,Guangzhou 510095;
    2.Department of Experiment Center,People′s Hospital of Guangdong Province,Guangzhou 510010
  • Received:2009-11-03 Online:2010-02-28 Published:2015-01-23

PDF (PC)

62

Abstract: Objective To explore the difference of serum protein mass spectrometry between the sensitive and drug resistance lung adenocarcinoma patients,and to discover serum protein markers for predicting chemotherapy sensitivity of lung adenocarcinoma patients.Methods To detect the protein mass spectrometry of 22 chemosensitive lung adenocarcinoma patients and 21 chemotherapy-resistant cases with WCX2 protein chip combining with SELDI-TOF-MS technique,and then screen differentially expressed proteins.Results In this experiment,7 differentially expressed proteins were screened,which can differentiate the chemosensitive or the chemotherapy-resistant patients with standard platinum-based chemotherapy.The m/z value of them is 16083.50Da,7963.17Da,16121.50Da,15921.60Da,8066.79Da,8040.17Da and 3394.57Da respectively.Predictive model with M/Z 7963.17Da and 16083.50Da could differentiate the chemosensitive or the chemotherapy-resistant patients,whose sensitivity was 86.36% and specificity was 80.95%.Conclusions SELDI-TOF-MS is an effective instrument to find sensitive serum marker for predicting lung adenocarcinoma chemotherapy sensitivity.

CLC Number: